Pulmonx Corp
LUNG2.490USD
-0.110-4.22%
Market hours （ET）Quotes delayed by 15 min
102.71MMarket Cap
LossP/E TTM
More Details of Pulmonx Corp Company
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Pulmonx Corp Info
Ticker SymbolLUNG
Company namePulmonx Corp
IPO dateOct 01, 2020
CEOFrench (Glendon E)
Number of employees291
Security typeOrdinary Share
Fiscal year-endOct 01
Address700 Chesapeake Dr
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16509342600
Websitehttps://pulmonx.com/
Ticker SymbolLUNG
IPO dateOct 01, 2020
CEOFrench (Glendon E)
Company Executives of Pulmonx Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Derrick Sung, Ph.D.
Dr. Derrick Sung, Ph.D.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.44M
+496.81%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
224.19K
-2.74%
Mr. Daniel P. (Dan) Florin
Mr. Daniel P. (Dan) Florin
Independent Director
Independent Director
78.69K
-22.86%
Mr. Richard M. (Rich) Ferrari
Mr. Richard M. (Rich) Ferrari
Independent Director
Independent Director
71.81K
+68.35%
Ms. Tiffany Sullivan
Ms. Tiffany Sullivan
Independent Director
Independent Director
59.98K
+162.74%
Mr. Thomas William Burns
Mr. Thomas William Burns
Independent Director
Independent Director
58.18K
+176.67%
Mr. Glendon E. (Glen) French
Mr. Glendon E. (Glen) French
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brian Johnston
Mr. Brian Johnston
Investor Relations
Investor Relations
--
--
Mr. David A. Lehman
Mr. David A. Lehman
General Counsel
General Counsel
--
--
Ms. Georgia Garinoismelenikiotou
Ms. Georgia Garinoismelenikiotou
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Derrick Sung, Ph.D.
Dr. Derrick Sung, Ph.D.
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
1.44M
+496.81%
Mr. Geoffrey Beran Rose
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Chief Commercial Officer
224.19K
-2.74%
Mr. Daniel P. (Dan) Florin
Mr. Daniel P. (Dan) Florin
Independent Director
Independent Director
78.69K
-22.86%
Mr. Richard M. (Rich) Ferrari
Mr. Richard M. (Rich) Ferrari
Independent Director
Independent Director
71.81K
+68.35%
Ms. Tiffany Sullivan
Ms. Tiffany Sullivan
Independent Director
Independent Director
59.98K
+162.74%
Mr. Thomas William Burns
Mr. Thomas William Burns
Independent Director
Independent Director
58.18K
+176.67%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
14.73M
61.74%
Europe, Middle-East and Africa ("EMEA")
7.00M
29.33%
Asia Pacific
2.03M
8.50%
Other International
102.00K
0.43%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
PRIMECAP Management Company
12.02%
Morgan Stanley & Co. LLC
8.36%
BlackRock Institutional Trust Company, N.A.
5.90%
The Vanguard Group, Inc.
5.44%
Fidelity Management & Research Company LLC
5.20%
Other
63.09%
Shareholders
Shareholders
Proportion
PRIMECAP Management Company
12.02%
Morgan Stanley & Co. LLC
8.36%
BlackRock Institutional Trust Company, N.A.
5.90%
The Vanguard Group, Inc.
5.44%
Fidelity Management & Research Company LLC
5.20%
Other
63.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.63%
Investment Advisor/Hedge Fund
14.96%
Hedge Fund
13.75%
Research Firm
11.77%
Individual Investor
10.76%
Venture Capital
0.42%
Sovereign Wealth Fund
0.37%
Pension Fund
0.21%
Bank and Trust
0.18%
Other
10.97%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
281
35.49M
87.11%
-7.28M
2025Q2
287
39.76M
97.74%
-2.93M
2025Q1
296
39.33M
97.70%
-4.34M
2024Q4
300
39.10M
98.27%
-6.73M
2024Q3
306
39.39M
100.59%
-8.60M
2024Q2
305
38.59M
99.39%
-11.14M
2024Q1
300
38.64M
99.54%
-10.45M
2023Q4
294
37.11M
96.84%
-10.90M
2023Q3
296
35.84M
94.15%
-16.29M
2023Q2
300
36.45M
96.58%
-16.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PRIMECAP Management Company
5.16M
12.68%
-250.08K
-4.62%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.94M
7.2%
+7.85K
+0.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.45M
6.01%
-88.33K
-3.48%
Jun 30, 2025
The Vanguard Group, Inc.
2.29M
5.63%
+11.68K
+0.51%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.23M
10.38%
-483.02K
-10.25%
Jun 30, 2025
French (Glendon E III)
906.89K
2.23%
+37.15K
+4.27%
Jun 02, 2025
Silvercrest Asset Management Group LLC
930.56K
2.28%
--
--
Jun 30, 2025
DWS Investments UK Limited
1.13M
2.76%
-6.19K
-0.55%
Jun 30, 2025
Geode Capital Management, L.L.C.
929.40K
2.28%
+1.86K
+0.20%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Broad Market ETF
0%
State Street SPDR S&P Health Care Equipment ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Avantis US Small Cap Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
State Street SPDR S&P Health Care Equipment ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Pulmonx Corp?
The top five shareholders of Pulmonx Corp are:
PRIMECAP Management Company holds 5.16M shares, accounting for 12.68% of the total shares.
Morgan Stanley & Co. LLC holds 2.94M shares, accounting for 7.20% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.45M shares, accounting for 6.01% of the total shares.
The Vanguard Group, Inc. holds 2.29M shares, accounting for 5.63% of the total shares.
Fidelity Management & Research Company LLC holds 4.23M shares, accounting for 10.38% of the total shares.
PRIMECAP Management Company holds 5.16M shares, accounting for 12.68% of the total shares.
Morgan Stanley & Co. LLC holds 2.94M shares, accounting for 7.20% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.45M shares, accounting for 6.01% of the total shares.
The Vanguard Group, Inc. holds 2.29M shares, accounting for 5.63% of the total shares.
Fidelity Management & Research Company LLC holds 4.23M shares, accounting for 10.38% of the total shares.
What are the top three shareholder types of Pulmonx Corp?
The top three shareholder types of Pulmonx Corp are:
PRIMECAP Management Company
Morgan Stanley & Co. LLC
BlackRock Institutional Trust Company, N.A.
PRIMECAP Management Company
Morgan Stanley & Co. LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Pulmonx Corp (LUNG)?
As of 2025Q3, 281 institutions hold shares of Pulmonx Corp, with a combined market value of approximately 35.49M, accounting for 87.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.64%.
What is the biggest source of revenue for Pulmonx Corp?
In FY2025Q2, the -- business generated the highest revenue for Pulmonx Corp, amounting to -- and accounting for --% of total revenue.
